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Adenocarcinoma of the appendix — case study
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The following study presents the case of a 58-year-old woman who was diagnosed, during the diagnosis of an ovar-
ian tumor, with mucous metastatic adenocarcinoma of the appendix. Due to the severity of the disease and the low 
degree of differentiation of the cancer, the treatment of the patient required a continuous and intensive systemic 
treatment lasting three years. A significant role in the course of the disease was also played by surgical interven-
tions, since the patient underwent 4 reoperations due to local recurrence. The history of the disease is an example 
of the problems in the therapy and diagnosis of atypical tumors resulting from non-specific symptoms and different 
evolution of the disease.
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Introduction
Colorectal cancer is the most common malignant tu-
mor in Europe. It is almost always adenocarcinoma and is 
located in most cases in the rectum and sigmoid colon [1]. In 
contrast, primary adenocarcinoma of the appendix is a very 
rare tumor, representing less than 0.5% of all gastrointestinal 
cancers [2]. In literature, only about 250 cases have been 
described [3, 4]. The illnesses are most often diagnosed in 
patients between 40 and 80 years of age [5].
There are two types of adenocarcinoma of the appen-
dix: mucinous adenocarcinoma and low-grade appendiceal 
mucinous neoplasm (LAMN) [1]. LAMN is characterised by 
the high degree of maturity of the cells, it grows slowly and 
spreads exclusively within the peritoneal cavity, creating an 
image of low-grade pseudomyxoma peritonei. On the other 
hand, mucinous adenocarcinoma invades the surrounding 
tissues and spreads through vessels [1, 2]. The most com-
mon location of metastases are the lymph nodes, peritoneal 
cavity and ovaries [6]. Ovarian metastases are diagnosed in 
10% of patients and in the majority (70–80%) of them, they 
have spread to both ovaries [7, 8].
Lack of specific symptoms of the primary cancer of the 
appendix makes the initial preoperative diagnosis usually 
acute appendicitis, more rarely a gastrointestinal obstruc-
tion or ovarian tumor [2, 5]. A proper diagnosis of the cancer 
is only achieved on the basis of a histological examination 
of the removed appendix. The prognosis of patients with 
primary cancer of the appendix is very serious. 32% of pa-
tients have a chance of 5-year survival [6, 9].
Case report
Since December 2010, a 54-year-old patient was being 
diagnosed due to episodic pains in the mesogastrium, which 
spontaneously receded. In the district hospital, on the basis 
of a gynecological consultation, laboratory and image tests 
(USG and CT of the abdomen, which revealed no pathologi-
cal changes), acute appendicitis and gynecological causes of 
the pain were excluded. A PET-CT examination was carried 
out, which noted an increased uptake of a marker in the 
right ovary plan.
In March 2011, the patient was qualified for surgery, 
with an initial diagnosis of a right ovarian tumor. In a his-
topathological examination, adenocarcinoma metastases 
were discovered. The range of operations was extended by 
performing hysterectomies and a right-sided hemicolec-
tomy with appendages. Based on the histopathological 
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examination of the procedute, mucinous adenocarcinoma 
of the appendix was diagnosed with a low degree of dif-
ferentiation (Adenocarcinoma mucinosum appendicis ver-
miformis G3) infiltrating the greater omentum, the right 
ovary and a lymph node.
In April 2011, the patient was in good general con-
dition (ECOG 0) and was admitted to the Department of 
Chemotherapy in the Clinic of Oncology in Poznan. In the 
physical examination, the patient complained about a slight 
abdominal pain in the right iliac fossa without the need for 
analgesics. The physical examination showed a scar after 
laparotomy without any evidence of recurrence and apart 
from that there were no abnormalities. The biochemical and 
morphotic parameters of blood were normal, with elevated 
tumor markers (CEA 5.1 ng/mL).
Due to the clinical advancement of pT4pN1M1, the pa-
tient was qualified for first-line palliative chemoimmuno-
therapy, following the FOLFIRI scheme with bevacizumab at 
a dose of 10 mg/kg. Anticipating long-term therapy for im-
proved comfort of the patient, a vascular port was applied, 
providing permanent access to the veins. Up until October 
2011, the patient received 12 courses every 14 days with 
good tolerance of the treatment being observed. The imag-
ing control examinations (a CT of the chest, abdomen and 
pelvis) did not report any lesions suggesting a cancerous 
process and decreased levels of CEA (3.4 ng/ml) were noted.
In December 2011, the patient complained about 
a severe abdominal pain around the right iliac fossa radiat-
ing to the right groin. Because of the clinical features of the 
disease progression, invisible in the imaging examinations 
(the MRI of the pelvis showed no local recurrence), an ex-
ploratory laparotomy was decided. In January 2012, a local 
recurrence resection was carried out (removal of a distal 
ureteral section with an implantation of a proximal ureter 
section to the bladder, a resection of the right internal iliac 
artery and a segmental resection of the ileum with the Val-
trac anastomosis). A PET-CT examination performed after 
the surgery showed no metabolic traits of recurrence or 
metastasis. From February to July 2012, the patient received 
12 courses of palliative, post-surgery chemotherapy follow-
ing the FOLFOX-4 scheme. The treatment was complicated 
by 3rd degree neutropenia (acc. CTCAE), requiring the use 
of G-CSF (filgrastim) in the secondary prevention.
In a PET-CT examination from August 2012 that evalu-
ated the foregoing therapy, an outbreak of local recurrence 
was revealed in the pelvis. The CEA level at the time was 
12.3 ng/mL. After an interdisciplinary consultation, the pa-
tient was qualified for a second reoperation during which 
a segmental resection of the sigmoid was done with an 
end-to-end anastomosis, and a segmental resection of the 
ileum with a side-to-side anastomosis.
In October 2012, a PET-CT, in which recurrences in the 
area of the post-seam ileum and an internal-right hip lymph 
node metastasis were detected, showed that surgery had 
proved ineffective. The possibility of molecularly targeted 
therapy was considered, but due to a (PCR test detected) 
mutation in exon 1 of the KRAS gene, the patient would 
not benefit from EGFR antagonists treatment (cetyksymab, 
pamitumumab). From November 2012 with third-line pallia-
tive chemotherapy, the patient received 4 courses of capecit-
abine (1250 mg/m2, 2 times a day for 14 days) every 21 days 
without clinical and marker improvement.
Due to the exhaustion of available methods of treat-
ment, a motion was filed to the National Health Fund to 
import a medicinal product — regorafenib from abroad. 
The drug in phase-III clinical studies showed better per-
formance in terms of OS compared to placebo in patients 
who suffered the progression of the disease after applying 
all standard therapies. Despite clinical indications and the 
legitimacy of the application, there was no consent from the 
National Health Fund for the above-mentioned treatment 
with the product.
In March 2013, the patient was admitted to the De-
partment of Chemotherapy in order to assess the current 
therapy of capecitabine. On admission, the patient reported 
the worsening of pain in the right hip radiating to the right 
groin, no stool for 5 days and constant fatigue. The over-
all health status of the patient was quite good (ECOG 1). 
A physical examination showed abnormalities: a palpable 
tumor in the right iliac fossa of about 5 cm in diameter. 
In laboratory tests, only small leukocytosis and 1st degree 
anemia (CTCAE) were found. 
After surgical consultation, intestinal obstruction was 
excluded, and, as a result of intensive symptomatic and 
analgesia treatment, an overall improvement of the pa-
tient’s state was achieved. An MRI of the pelvis revealed 
a pathological mass sized 70 × 54 × 85 mm around the right 
iliac fossa, infiltrating the pelvic muscles, iliac vessels, and 
the bladder wall.
Due to significant clinical and marker progression (CEA 
426 ng/mL), the patient was proposed treatment under 
clinical testing with regorafenib. She approved it and started 
an oral regorafenib treatment in the open clinical testing 
of phase III b (BAY 73-4506/15967) with a dose of 160 mg 
per day (1 × 4 tab. of 40 mg each for 21 days) every 28 
days. After the first treatment cycle, the concentration of 
CEA decreased (319 ng/mL) and the improvement of the 
general condition of the patient was reached, including 
less pain and the normalisation of bowel habits. There were 
also no side effects of the treatment. On the basis of the 
MRI, the first evaluation of the efficacy of the treatment 
after 3 cycles demonstrated regression of the lesion size 
(45 mm in diameter, without evidence of infiltration of the 
bladder) and the decrease in the concentration of CEA to 
286 ng/mL. Due to improved tolerance, partial radiological 
remission and decrease in tumor markers, it was decided to 
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continue the regorafenib therapy. In the 4-cycle due to 3rd 
degree anemia (according to CTCAE) and a lower urinary 
tract infection, the patient required a transfusion of 2 units 
of PRBC and antibiotic therapy.
Due to recurring symptoms of the urinary tract infection 
and the presence of fecal matter in general urine analysis, 
in July 2013 a PET-CT examination was performed, which 
confirmed the presence of a intestinovesicular fistula. The 
patient was qualified for surgery. A bypass anastomosis was 
performed within the jejunum and ileum.
After the 6th series of regorafenib immunotherapy, the 
patient began to lose weight steadily with good appetite, 
reaching the lowest weight during cycle 9 (3 deg. according 
to CTCAE), which was the reason for the reduction of the 
dose to 80 mg per day. Cycle 7 and 10 have been compli-
cated by 3rd degree anemia (acc. CTCAE), requiring a trans-
fusion of PRBC. A radiographic CT scan in November 2013 
showed an increase in the size of the lesion in the right iliac 
fossa (81 × 64 mm), intestinovesicular fistula characteristics 
and a pressure onto the right internal obturator muscle.
In December 2013, the patient underwent another 
emergency reoperation due to an intestinal-vaginal fistula. 
A loop ileostomy was performed, achieving an improvement 
in the clinical condition of the patient.
Given the radiological and marker progression of the 
disease, as well as the weakening condition of the patient, 
emaciated by the intensive, multimedicine treatment which 
had lasted three years without interruption, it was decided 
to end the regorafenib immunotherapy after 10 cycles. For 
three months, the patient was under the care of a hospice, 
where, despite the best supportive care, the pain in her right 
lower abdomen intensified. There was also a partial paralysis 
of the right lower limb. In March 2014, 12 months after the 
start of regorafenib therapy, the patient died at home.
Summary
From the moment of the diagnosis of advanced ad-
enocarcinoma of the appendix to the death of the patient, 
it was over 36 months; from the start of the regorafenib 
therapy, it was 12 months. Analysing the described case 
and the results of examination phase III CORRECT (in the 
group with regorafenib median OS — 6.4 months, and in 
the placebo group — 5.0 months (HR = 0.77, p = 0.0052), 
it can be certainly concluded that the patient received 
a clinical benefit from this treatment.
In clinical practice, this means that a monotherapy with 
this multikinase inhibitor can stabilise the disease for some 
time and consequently prolong the life of patients, who 
Table I. Efficacy results obtained in the test CORRECT
Efficacy Parameter Hazard ratio* (95% CI) Value p (unilateral) Median (95% CI) Stivarga 
plus BSC (n = 505)
Median (95% CI) Placebo 
plus BSC (n = 255)
Overall survival 0.774 (0.636, 0.942) 0.005178 6.4 months (5.9, 7.3) 5.0 months (4.4, 5.8)
Progression-free survival ** 0.494 (0.419, 0.582) < 0.000001 1.9 months (1.9, 2.1) 1.7 months (1.7, 1.7)
§Best Supportive Care 
*The hazard ratio < 1 favors the Stivarga medicinal product 
**Based on the investigator’s assessment of the tumor response
Figure. 1 CEA concentrations during the therapy [ng/mL]
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are in good general condition and do not have any other 
treatment options. It is also worth noting that the patient 
tolerated the treatment well, and apart from losing weight, 
did not present any typical regorafenib side effects, such as 
hand-foot syndrome and hypertension. This would indicate 
that the side effects of the treatment may be due to the 
long prior chemotherapy and the progress of the disease.
Abbreviations: 
CEA — carcinoembryonic antigen
CT— computed tomography
CTCAE — the evaluation scale of the toxicity of treatment 
(Common Terminology Criteria for Adverse Events)
ECOG — the scale of performance by the Eastern Coopera-
tive Oncology Group
FOLFIRI — fluorouracil 400 mg/m2 in a bolus and 600 mg/m2 
in a 48-hour infusion, calcium folinate 200 mg/m2 in a 2-hour 
infusion, irinotecan 150 mg/m2
FOLFOX-4 — oxaliplatin 85 mg/m2 in a 2-hour infusion, flu-
orouracil 400 mg/m2 in a bolus and 600 mg/m2 in a 48-hour 
infusion, calcium folinate 200 mg/m2 in a 2-hour infusion
G-CSF — granulocyte colony stimulating factor
OS — overall survival time 
PFS — progression-free survival time
PRBC — the concentration of red blood cells
QoL — quality of life
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